Literature DB >> 18580209

Transoral endoscopic fundoplication in the treatment of gastroesophageal reflux disease: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel device.

Blair A Jobe1, Robert W O'Rourke, Barry P McMahon, Flemming Gravesen, Cedric Lorenzo, John G Hunter, Mary Bronner, Stefan J M Kraemer.   

Abstract

OBJECTIVE: To determine the safety, mechanism of action, immediate postprocedural anatomic impact on the esophagogastric junction, and short-term efficacy of the first entirely endolumenal antireflux procedure.
BACKGROUND: A safe and effective endoscopic antireflux procedure remains elusive. Transoral endolumenal surgery has enormous potential for the treatment of gastroesophageal reflux disease (GERD) and other esophagogastric diseases. A canine model was used to study a novel endoscopic device, which allows for creation of an endoluminal fundoplication.
METHODS: The transoral incisionless fundoplication (TIF) was performed in 21 canines in a phase I feasibility and safety study, and in 21 canines in a phase II study that included a detailed objective assessment of the effects of 2 variants of the TIF procedure (TIF 1.0 and TIF 2.0) versus sham on esophageal physiology and esophagogastric junction (EGJ) anatomy.
RESULTS: In phase I, TIF provided a safe and feasible endolumenal therapy for GERD, with histologic data that demonstrated serosal fusion of approximated full-thickness tissue plications and durability of the fundoplication. TIF procedures effectively reduced cardia circumference and improved Hill classification grade. In phase II, the TIF 2.0 procedure achieved normalization of distal esophageal acid exposure and increased lower esophageal sphincter (LES) pressure and length based on objective testing over a 2-week period. TIF 2.0 demonstrated superior results to TIF 1.0, and valve appearance and location exhibited similarity to the Nissen fundoplication by vector volume analysis.
CONCLUSIONS: The TIF procedure is safe and results in a durable and functional fundoplication as well as a platform for further development and modification of the procedure, which can be use to impact outcome. This work provides the foundation for human translation and assessment of long-term outcomes.

Entities:  

Mesh:

Year:  2008        PMID: 18580209     DOI: 10.1097/SLA.0b013e31817c9630

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Endoscopic treatments for gastroesophageal reflux disease.

Authors:  Blair A Jobe
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-01

2.  Transoral incisionless fundoplication 2.0 procedure using EsophyX™ for gastroesophageal reflux disease.

Authors:  Toshitaka Hoppo; Arul Immanuel; Matthew Schuchert; Zdenek Dubrava; Andrew Smith; Peter Nottle; David I Watson; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2010-09-28       Impact factor: 3.452

3.  Endoscopic fundoplication: real or fantasy?

Authors:  Alejandro Nieponice; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2011-06-10       Impact factor: 3.452

4.  Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.

Authors:  Bart P L Witteman; Jose M Conchillo; Nicolaas F Rinsma; Bark Betzel; Andrea Peeters; Ger H Koek; Laurents P S Stassen; Nicole D Bouvy
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

5.  New Approaches to Gastroesophageal Reflux Disease.

Authors:  William Kethman; Mary Hawn
Journal:  J Gastrointest Surg       Date:  2017-06-16       Impact factor: 3.452

6.  Revision of failed transoral incisionless fundoplication by subsequent laparoscopic Nissen fundoplication.

Authors:  Awais Ashfaq; Hyun K Daniel Rhee; Kristi L Harold
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Long-term efficacy of transoral incisionless fundoplication with Esophyx (Tif 2.0) and factors affecting outcomes in GERD patients followed for up to 6 years: a prospective single-center study.

Authors:  Pier Alberto Testoni; Sabrina Testoni; Giorgia Mazzoleni; Cristian Vailati; Sandro Passaretti
Journal:  Surg Endosc       Date:  2014-12-06       Impact factor: 4.584

8.  Initial experience with new intraluminal devices for GERD, Barrett's esophagus, and obesity.

Authors:  Charles J Filipi; Rudolf J Stadlhuber
Journal:  J Gastrointest Surg       Date:  2009-09-24       Impact factor: 3.452

9.  Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience.

Authors:  Alessandro Repici; Uberto Fumagalli; Alberto Malesci; Roberta Barbera; Camilla Gambaro; Riccardo Rosati
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

10.  Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients.

Authors:  Pier Alberto Testoni; Maura Corsetti; Salvatore Di Pietro; Antonio Gianluca Castellaneta; Cristian Vailati; Enzo Masci; Sandro Passaretti
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.